# A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

> clinical trial · VERIFIED · 2026-07-20

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Endometrial Cancer

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06952504

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.